Triazolo compounds as MMP inhibitors

Details Triazolo compounds as MMP inhibitors Triazolo compounds as MMP inhibitors

2005-02-01

2005-02-01

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S250000, C544S251000

Reexamination Certificate

active

06849637

ABSTRACT:
A compound selected from those of formula (I):in which:W represents N or C—R1; in which R1is as defined in the description,X represents N or C—R2in which R2is as defined in the description,Y represents a group selected from oxygen, sulfur, —NH, and —Nalkyl,Z represents a group selected from oxygen, sulphur, —NR8in which R8is as defined in the description, and optionally carbon depending the definition of Y,n is an integer from 0 to 8 inclusive,Z1represents a group —CR9R10wherein R9and R10, are as defined in the description, which group contains optionally multiple bonds or heteroatomes,A represents a cyclic group,m is an integer from 0 to 7 inclusive,the group(s) R4is (are) as defined in the description,R3represents a group selected from hydrogen, alkyl, alkenyl, alkynyl, and the group of formula:in which p, Z2, B, q, and R13are as defined in the description,optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its the pharmaceutically acceptable salts thereof, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix mettaloprotease.

REFERENCES:
patent: 4455311 (1984-06-01), Kienzle
patent: 5948780 (1999-09-01), Peterson, Jr. et al.
patent: 6008243 (1999-12-01), Bender et al.
patent: 20020193377 (2002-12-01), Andrianjara et al.
patent: 20030078276 (2003-04-01), Andrianjara et al.
patent: 20030130278 (2003-07-01), Gaudilliere et al.
patent: 20030144274 (2003-07-01), Bunker et al.
patent: 20030216402 (2003-11-01), Gaudilliere et al.
patent: 20030220355 (2003-11-01), Gaudilliere et al.
patent: 20040006077 (2004-01-01), Gaudilliere et al.
patent: 20040063673 (2004-04-01), Johnson
patent: 0 076 199 (1983-04-01), None
patent: 0 217 748 (1987-04-01), None
patent: 0935963 (1999-08-01), None
patent: 1138680 (2001-10-01), None
patent: WO 0009485 (2000-02-01), None
patent: WO 0066584 (2000-04-01), None
patent: WO 0112611 (2001-02-01), None
patent: WO 0163244 (2001-08-01), None
patent: WO 0234726 (2002-05-01), None
patent: WO 0234753 (2002-05-01), None
patent: WO02064080 (2002-08-01), None
patent: WO 02064080 (2002-08-01), None
patent: WO02064080 (2002-08-01), None
patent: WO 02064572 (2002-08-01), None
patent: WO02064572 (2002-08-01), None
patent: WO02064595 (2002-08-01), None
patent: WO03032999 (2003-04-01), None
patent: WO03033478 (2003-04-01), None
patent: WO03076417 (2003-09-01), None
patent: WO03076417 (2003-09-01), None
patent: WO04000322 (2003-12-01), None
Beers et al., Crohn's Disease; Ulcerative Colitis; Psoriasis, The Merck Manual of Diagnosis and Therapy, Seventeenth Edition (online), 1999.*
Casanova et al., PubMed Abstract (Rev. Neurol. 28(9):909-15) May 1999.*
Bremner et al., Therapy of Crohn's Disease in childhoo, Exp. Opin. Pharmacother. 3(70:809-825, 2002.*
Robinson, Medical Therapy of Inflammatory Bowel Disease for the 21st century, Eur. J. Surg. Suppl. 582:90-98, 1998.*
Singh et al., Immune Therapy in Inflammatory Bowel Disease and models of colitis, British Journal of Surgery, 88, pp. 1558-1569, 2001.*
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.*
Morris et al., PubMed Abstract (Invasion Metastasis, 17(6):281-96), 1997.*
Rasmussen et al., Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy, Pharmacol. Ther., vol. 75, No. 1, pp. 69-75, 1997.*
Chambers et al., Changing Views of the Role of Matrix Metalloproteinases in Metastasis, Journal of National Cancer Institute, vol. 89, No. 17, Sep. 1997.*
Lovejoy et al., “Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors”, Nature Structural Biology, 1999, vol. 6, No. 3, pp. 217-221.
Moy et al., “High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-13) Complexed with a Hydroxamic Acid Inhibitor”, J. Mol. Biol., 2000, vol. 302, 671-689.
Mitchell et al., “Cloning Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin. Invest., 1996, vol. 97, No. 3, pp. 761-768.
Neuhold et al., “Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) reduces osteoarthritis in mice”, J. Clin. Invest., 2001, vol. 107, No. 1, pp. 35-44.
Dahlberg et al., “Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritis Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase 1 (Matrix Metalloproteinase 1)”, Arthrit. & Rheum., 2000, vol. 43, No. 3, pp. 673-682.
Billinghurst et al., “Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleukin-1 and the Selection Inhibition of Type II Collagen Cleavage by Collagenase”, Arthrit. & Rheum., 2000, vol. 43, No. 3, pp. 664-672.
Billinghurst et al., “Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage”, J. Clin. Invest., 1997, vol. 99, No. 7, pp. 1534-1545.
Hirota et al., “Novel Synthesis of Pyrido[3,4-d]pyrimidines, Pyrido[2,3-d]pyrimidines, and Quinazolines via Palladium-Catalyzed Oxidative Coupling”, Heterocycles, 1994, vol. 37, No. 1, pp. 563-570.
U.S. Appl. No. 10/634,473, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,289, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,180, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,712, filed Aug. 5, 2003, Hicks et al.
U.S. Appl. No. 10/634,181, filed Aug. 5, 2003, Li.
U.S. Appl. No. 10/634,489, filed Aug. 5, 2003, Roark.
U.S. Appl. No. 10/634,420, filed Aug. 5, 2003, Roark.
U.S. Appl. No. 10/634,716, filed Aug. 5, 2003, Nahra et al.
U.S. Appl. No. 10/634,288, filed Aug. 5, 2003, O'Brien.
U.S. Appl. No. 10/634,182, filed Aug. 5, 2003, Li.
U.S. Appl. No. 10/734,718, filed Aug. 5, 2003, Ortwine.
Montana, John, et al, “The design of selective non-substrate-based matrix metalloproteinase inhibitors”, Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361.
Clark, Ian, et al, “Matrix metalloproteinase inhibitors in the treatment of arthritis”, Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25.
Chen, James, et al, “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design”, J. Am. Chem. Soc., 2000, 122; pp 9648-9654.

Affiliated with

Also associated with

Rating

Triazolo compounds as MMP inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Triazolo compounds as MMP inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolo compounds as MMP inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3502599